Terms: = Lung cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Staging
418 results:
1. Novel Functional Radiomics for Prediction of Cardiac Positron Emission Tomography Avidity in lung cancer Radiotherapy.
Choi W; Jia Y; Kwak J; Werner-Wasik M; Dicker AP; Simone NL; Storozynsky E; Jain V; Vinogradskiy Y
JCO Clin Cancer Inform; 2024 Mar; 8():e2300241. PubMed ID: 38452302
[TBL] [Abstract] [Full Text] [Related]
2. Correlation Analysis of KCNQ1 Gene Polymorphism with Blood Indexes and Prognosis of Non-Small Cell lung cancer.
Xie G; Yang Y; Zeng W; Liu Y; Gui B
Clin Lab; 2024 Feb; 70(2):. PubMed ID: 38345992
[TBL] [Abstract] [Full Text] [Related]
3. Surgeon experience does not influence nodal upstaging during vats lobectomy: Results from a large prospective national database.
Chiappetta M; Lococo F; Sperduti I; Tabacco D; Sassorossi C; Curcio C; Crisci R; Meacci E; Rea F; Margaritora S;
Surgery; 2024 May; 175(5):1408-1415. PubMed ID: 38302325
[TBL] [Abstract] [Full Text] [Related]
4. Head-to-head comparison of
Zhang M; Liu Z; Yuan Y; Yang W; Cao X; Ma M; Han B
Diagn Interv Radiol; 2024 Mar; 30(2):99-106. PubMed ID: 38291975
[TBL] [Abstract] [Full Text] [Related]
5. Performance of EUS-FNA and EUS-B-FNA for the diagnosis of left adrenal glands metastases in patients with lung cancer: A systematic review and meta-analysis.
Moretti A; Kovacevic B; Vilmann P; Annema JT; Korevaar DA
Lung Cancer; 2023 Dec; 186():107391. PubMed ID: 37827042
[TBL] [Abstract] [Full Text] [Related]
6. ChatGPT: Can You Prepare My Patients for [
Rogasch JMM; Metzger G; Preisler M; Galler M; Thiele F; Brenner W; Feldhaus F; Wetz C; Amthauer H; Furth C; Schatka I
J Nucl Med; 2023 Dec; 64(12):1876-1879. PubMed ID: 37709536
[TBL] [Abstract] [Full Text] [Related]
7. Diagnostic performance and prognostic value of CT-defined visceral pleural invasion in early-stage lung adenocarcinomas.
Lim WH; Lee KH; Lee JH; Park H; Nam JG; Hwang EJ; Chung JH; Goo JM; Park S; Kim YT; Kim H
Eur Radiol; 2024 Mar; 34(3):1934-1945. PubMed ID: 37658899
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of hypermetabolic mediastinal-hilar lymph nodes determined by PET/CT with EBUS-TBNA and calculation of SUVmax cutoff values in differentiation of malignancy.
Ugurlu E; Metin M; Cetin N; Kilicarslan E; Degirmencioglu S; Sengoz T; Akbudak IH; Gokoz Dogu G; Aydogmus U
Medicine (Baltimore); 2023 Sep; 102(35):e34928. PubMed ID: 37657039
[TBL] [Abstract] [Full Text] [Related]
9. Impact of skip mediastinal lymph node metastasis on outcomes after resection for primary lung cancer.
Taylor M; Soliman N; Paoletti E; King M; Crosbie PAJ; Granato F
Lung Cancer; 2023 Oct; 184():107341. PubMed ID: 37573704
[TBL] [Abstract] [Full Text] [Related]
10. Diagnostic potential of [
Zhang M; Yang W; Yuan Y; Liu Z; Yue X; Cao X; Han B
Jpn J Radiol; 2024 Jan; 42(1):87-95. PubMed ID: 37566187
[TBL] [Abstract] [Full Text] [Related]
11. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.
Hottat NA; Badr DA; Ben Ghanem M; Besse-Hammer T; Lecomte SM; Vansteelandt C; Lecomte SL; Khaled C; De Grove V; Salem Wehbe G; Cannie MM; Jani JC
Eur Radiol; 2024 Jan; 34(1):165-178. PubMed ID: 37555959
[TBL] [Abstract] [Full Text] [Related]
12. [
Yang L; Xu S; Cheng L; Gao C; Cao S; Chang Z; Wang K
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4051-4063. PubMed ID: 37542659
[TBL] [Abstract] [Full Text] [Related]
13. Diagnostic performance of whole-body [
Mirshahvalad SA; Kohan A; Metser U; Hinzpeter R; Ortega C; Farag A; Veit-Haibach P
Eur Radiol; 2024 Jan; 34(1):673-685. PubMed ID: 37535156
[TBL] [Abstract] [Full Text] [Related]
14.
Kersting D; Sandach P; Sraieb M; Wiesweg M; Metzenmacher M; Darwiche K; Oezkan F; Bölükbas S; Stuschke M; Umutlu L; Nader M; Hamacher R; Fendler WP; Wienker J; Eberhardt WEE; Schuler M; Herrmann K; Hautzel H
J Nucl Med; 2023 Oct; 64(10):1540-1549. PubMed ID: 37474272
[TBL] [Abstract] [Full Text] [Related]
15. Economic burden of lung cancer in Morocco: A cost of illness study.
El Harch I; Guendaoui S; Charkaoui M; Benmaamar S; Omari M; El Youbi M; Belakhhel L; Abouselham L; Hachri H; El Menchay I; El Fakir S; Berraho M; Benchekroun N; Tachfouti N
J Cancer Policy; 2023 Sep; 37():100428. PubMed ID: 37353003
[TBL] [Abstract] [Full Text] [Related]
16. PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort.
Brose A; Michalski K; Ruf J; Tosch M; Eschmann SM; Schreckenberger M; König J; Nestle U; Miederer M
Cancer Imaging; 2023 May; 23(1):45. PubMed ID: 37198668
[TBL] [Abstract] [Full Text] [Related]
17. Head-to-Head Comparison of [
Ballal S; Yadav MP; Roesch F; Raju S; Satapathy S; Sheokand P; Moon ES; Martin M; Awarwal S; Tripathi M; Bal C
Thyroid; 2023 Aug; 33(8):974-982. PubMed ID: 37171126
[No Abstract] [Full Text] [Related]
18. Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non-Small-Cell lung cancer in a Large Community Oncology Practice.
Waterhouse DM; Ward P; Arnal S; Neubauer M; Drosick DR; Davies D; Mendenhall MA
JCO Oncol Pract; 2023 Jun; 19(6):e951-e956. PubMed ID: 37126768
[TBL] [Abstract] [Full Text] [Related]
19. The value of folate receptor-positive circulating tumor cells in the diagnosis of lung cancer and its correlation with clinical characteristics.
Xu Y; Li Q; Lin Z; Lin Y
Clin Respir J; 2023 May; 17(5):374-383. PubMed ID: 36977421
[TBL] [Abstract] [Full Text] [Related]
20. Prescreening in oncology trials using medical records. Natural language processing applied on lung cancer multidisciplinary team meeting reports.
Ansoborlo M; Gaborit C; Grammatico-Guillon L; Cuggia M; Bouzille G
Health Informatics J; 2023; 29(1):14604582221146709. PubMed ID: 36964666
[TBL] [Abstract] [Full Text] [Related]
[Next]
